March 30, 2015

Encapsulated Cell Technology Could Replace Injections in Wet AMD Patients

by

Encapsulated Cell Technology Could Replace Injections in Wet AMD Patients

Neurotech Pharmaceuticals, Inc. announced on March 30, 2015 that the FDA has approved a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of wet age-related macular degeneration (AMD).
ECT is an intravitreal implant that is genetically engineered to produce the biologic anti-VEGF drug NT-503 for at least 2 years. ECT, therefore, acts like a miniature factory for production and distribution of antiangiogenic and anti-inflammatory drugs in AMD patients long-term without the burden and risks of frequent injections.
The study will commence immediately and enroll 150 patients.  The safety and efficacy of one NT-503 ECT implant will be compared to Eylea injections every 8 weeks in patients who have been treated with at least 3 anti-VEGF injections and still have active disease.  Patients will be followed for 2 years with a 12-month interim assessment.
More about ECT research

We offer resources and free materials for those living with low vision.

View Resources